Advice
Following a resubmission
aliskiren (Rasilez) is not recommended for use within NHS Scotland for the treatment of essential hypertension.
Aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, though its effects on mortality and long-term morbidity are currently unknown.
The manufacturer did not present a sufficiently robust clinical or economic analysis to gain acceptance by the SMC for the position sought.
Download detailed advice96KB (PDF)
Medicine details
- Medicine name:
- aliskiren (Rasilez)
- SMC ID:
- 462/08
- Indication:
- Essential Hypertension
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 08 February 2010